title: Long-term efficacy of trilostane for Cushing's syndrome due to adrenocorticotropin-independent bilateral macronodular adrenocortical hyperplasia.
abstract: A 66-year-old man with Cushing's syndrome due to adrenocorticotropin-independent bilateral macronodular adrenocortical hyperplasia (AIMAH) was treated for 7 years with trilostane, a 3β-hydroxysteroid dehydrogenase inhibitor. Administration of trilostane reduced the serum cortisol level to around the upper limit of normal for 7 years, and symptoms of excessive glucocorticoid production (such as moon face and obesity) were gradually improved. On the other hand, the size of both adrenal glands gradually increased despite treatment with trilostane. Though trilostane therapy could not prevent adrenal growth, it did suppress cortisol secretion over the long term, so it might be a reasonable option for AIMAH in addition to adrenalectomy.
authors: Department of Endocrinology and Metabolism, Sumitomo Hospital, Japan.
authors: Yoshinari
authors: Y
authors: Obata
authors: Yuya
authors: Y
authors: Yamada
authors: Megu Yamaguchi
authors: MY
authors: Baden
authors: Yoshiya
authors: Y
authors: Hosokawa
authors: Kenji
authors: K
authors: Saisho
authors: Sachiko
authors: S
authors: Tamba
authors: Koji
authors: K
authors: Yamamoto
authors: Yuji
authors: Y
authors: Matsuzawa
mesh_terms: D000311:Adrenal Glands / Q000187:drug effects* / Q000473:pathology*; D000324:Adrenocorticotropic Hormone / Q000502:physiology*; D003480:Cushing Syndrome / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D013196:Dihydrotestosterone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D006965:Hyperplasia; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D013196:Dihydrotestosterone; D000324:Adrenocorticotropic Hormone; C009954:trilostane